The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

DoP extends timeline for industry to file self-declaration under UCPMP for FY 2024-25: Gireesh Babu, New Delhi Monday, August 4, 2025, 08:00 Hrs [IST] The Department of Pharmaceut ...

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Trump is using Section 232 and his Most Favoured Nation policy as twin levers in his push to lower drug prices.

Madbouly affirmed the government’s interest in providing all necessary support for the growth and localisation of this vital industry ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and ...

Why pharma companies' "price transparency" reports paint a murky picture of how much Americans spend on prescription drugs.

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Thermo Fisher shows signs of post-COVID recovery, but modest growth, valuation risks, and macro pressures warrant caution.

A 492-strong Cardiff-based pharmaceutical firm has posted a fall in turnover and profits in its latest year amid a decrease ...

Switzerland's government was due to hold an extraordinary cabinet meeting on Monday to discuss its response to President ...